Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celularity Inc Capital/Financing Update 2025

Jan 24, 2025

34506_rns_2025-01-24_c389f93f-07cd-4925-a467-16ac1217016a.zip

Capital/Financing Update

Open in viewer

Opens in your device viewer

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 23, 2025

Field: Rule-Page

Field: /Rule-Page

Celularity Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-38914 83-1702591
(State
or other jurisdiction of
incorporation) (Commission File
Number) (IRS
Employer Identification
No.)

| 170
Park Ave Florham
Park , New Jersey | 07932 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

Registrant’s telephone number, including area code: (908) 768-2170

N/A

(Former name or former address, if changed since last report.)

Field: Rule-Page

Field: /Rule-Page

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| --- | --- |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title
of each class | Trading
Symbol(s) | Name
of each exchange on which registered |
| --- | --- | --- |
| Class
A Common Stock, $0.0001 par value per share | CELU | The
Nasdaq Stock Market LLC |
| Warrants,
each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of $11.50 per share | CELUW | The
Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 1.02 Termination of a Material Definitive Agreement

As previously disclosed on January 3, 2025, Celularity Inc. (the “Company”) announced that it had entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”) of (i) 1,263,157 shares of the Company’s Class A common stock, par value $0.0001 (the “Common Stock”) and (ii) warrants (the “Common Warrants”) to purchase up to 1,263,157 shares of the Company’s Common Stock, at a purchase price of $2.375 per share of Common Stock and accompanying warrants.

On January 23, 2025, the Company notified the Purchaser that pursuant to Section 5.1 of the Purchase Agreement, the Purchase Agreement had expired and due to non-receipt by the Company of the subscription amount, the Private Placement would not be consummated.

Field: Page; Sequence: 2; Options: NewSection; Value: 2

  • 2 -

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:
January 24, 2025
By: /s/
Robert J. Hariri
Name: Robert
J. Hariri, M.D., Ph.D.
Title: Chairman
and CEO

Field: Page; Sequence: 3; Options: Last

  • 3 -

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJyFUc1Kw0AQfoK+wxB6rHUTrYfcaqgiVhtqUa/TdGIXk50wu631kXxLdzcWQQVDIBnm+91NklFyzVe6IYHny+UcVtR2DTqCJdUkZCryiOLmNgf/XdKLtk7QuDgeiQV7DnnOZJxN0C8idK8tbXJQ6Wl2fppNQJ3nZxdQ3iWDsC/Y1HpDxmlsAM0GSuFONDmU915hhQc23L5Hq0cSq9nkkI5Vv/6ATKUZ3PMe31heLcznRTIYxWeQXAvvOo+aHRyZwIRZQ623sz37+41pqp113OZPKKGcnWG1nR1IKm1x3dAVy8L4fsZtF7X/e9ii0KIuGrTWd2/ZPDiuXqfui0Ol6MoD0nQ8USVJxN9RuybxXqnKslRNv2ocLUdA3hTo2xVqFmBDJ9EYuA4D2KAVhugOU+gDQEwA6PxZHkUIupAjgIcxCnT+sqLAH91/tlFjpVRaojxis6N/WvwVZgTDXgM6FNgHld8BPgHl9ceI